Combination of Pembrolizumab With Platinum-containing Chemotherapy for Pulmonary Enteric Adenocarcinoma | Zendy

Shuhei Teranishi | Zendy; Chihiro Sugimoto | Zendy; Hidetoshi Nagayama | Zendy; Wataru Segawa | Zendy; Atsushi Miyasaka | Zendy; Shuntaro Hiro | Zendy; Chihiro Maeda | Zendy; Hironori Tamura | Zendy; Nami Masumoto | Zendy; Yoshinori Nagahara | Zendy; Nobuyuki Hirama | Zendy; Nobuaki Kobayashi | Zendy; Masaki Yamamoto | Zendy; Makoto Kudo | Zendy; Takeshi Kaneko | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Combination of Pembrolizumab With Platinum-containing Chemotherapy for Pulmonary Enteric Adenocarcinoma

Author(s) -

Shuhei Teranishi,

Chihiro Sugimoto,

Hidetoshi Nagayama,

Wataru Segawa,

Atsushi Miyasaka,

Shuntaro Hiro,

Chihiro Maeda,

Hironori Tamura,

Nami Masumoto,

Yoshinori Nagahara,

Nobuyuki Hirama,

Nobuaki Kobayashi,

Masaki Yamamoto,

Makoto Kudo,

Takeshi Kaneko

Publication year - 2022

Publication title -

cancer diagnosis and prognosis

Language(s) - English

Resource type - Journals

ISSN - 2732-7787

DOI - 10.21873/cdp.10102

Subject(s) - pembrolizumab , chemotherapy , medicine , adenocarcinoma , lung cancer , oncology , small cell carcinoma , cancer , immunotherapy

Pulmonary enteric adeno-carcinoma (PEAC) is a rare type of non-small cell lung cancer (NSCLC), for which no established standard treatment exists. Combination therapy with the anti-programmed cell death protein 1 antibody pembrolizumab and platinum-containing chemotherapy is the standard treatment for NSCLC patients, but its effectiveness in PEAC is uncertain.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research